Navigation Links
Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
Date:11/19/2009

$92,084 at December 31, 2008 91,019 89,168 Shareholders' equity (deficit): Preferred stock, par value $0.01 per share: Authorized shares - 13,425,919 at September 30, 2009 (unaudited) and December 31, 2008 Designated convertible - 13,425,919 at September 30, 2009 (unaudited) and December 31, 2008 - - Common stock, par value $0.01 per share: Authorized shares - 20,410,000 at September 30, 2009 (unaudited) and December 31, 2008; Issued and outstanding shares-2,930,167 and 2,951,406 at September 30, 2009 (unaudited) and December 31, 2008, respectively 30 30 Additional paid-in capital 7,408 6,150 Accumulated other comprehensive loss 23 (99) Deficit accumulated during the development stage (112,754) (97,247) -------- ------- Total shareholders' deficit (105,293) (91,166) -------- ------- Total liabilities, convertible preferred stock, and shareholders' equity (deficit) $6,910 $21,681 ====== =======

SOURCE Omeros Corporation


'/>"/>
SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
2. Omeros Appoints David A. Mann to its Board of Directors
3. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
4. Omeros and BlueCrest Announce $20 Million Debt Facility
5. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
6. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
7. Omeros Appoints New Vice President of Clinical Development
8. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
9. Omeros Commences Initial Public Offering of Common Stock
10. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
11. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Westlake Village, Calif. (PRWEB) January 15, 2014 ... cancer treatment and management through the genomic analysis of ... will offer Therapy Finder™, a web-based cancer decision support ... a reporting option with Cynvenio’s ClearID™ genomic test, Therapy ...
(Date:1/15/2014)... IPSWICH, England , January 15, 2014 ... to win races on the Formula 1 track could help ... between McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based ... funded by healthcare provider Simplyhealth. Telemetry technology, which ...
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to announce ... organizations who need document translations. Clients will now have ... in advance with a selection of nearly 50 life science ... critical factor in clinical and scientific fields, and decrease the ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... Inc. ("OriGene") today announced it has raised an ... With this financing, OriGene completed the acquisition of ... a manufacturer and provider of monoclonal antibodies (mAb) ... completes the establishment of its technology center to ...
... NKTR ) will announce its financial results ... on Wednesday, February 25, 2009, after the close,of U.S.-based ... will host a conference call to review the results ... (PT). , The press release ...
... VALLEY COTTAGE, N.Y., Feb. 11 XTL,Biopharmaceuticals Ltd. (Nasdaq: ... Mr.,David Grossman and Mr. Boaz Shweiger have been appointed ... Mr. Grossman will also be assuming,the role of Co-Chief ... of its strategic alternatives. , ...
Cached Biology Technology:OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China 2Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets 2XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors 2XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors 3
(Date:4/17/2014)... IPCC meeting painted a stark warning on the possible ... a greenhouse effect 32 times that of carbon dioxide. ... humic substances act as fully regenerable electron acceptors which ... in wetlands instead of being released to the atmosphere. ... disrupted it may enter into a vicious cycle to ...
(Date:4/17/2014)... Branch at Galveston are the first to recommend ... cancer should begin colorectal cancer screening earlier than ... a high incidence of secondary colorectal cancers among ... recommendations that the younger women in this group ... their initial cervical cancer diagnosis instead of waiting ...
(Date:4/17/2014)... a special feature of The Proceedings ... ) published April 29, raises a number of startling ... most of us take for granted. At the end ... around the globe shifted from hunting animals and gathering ... It seems so straightforward and yet the more scientists ...
Breaking Biology News(10 mins):Methane climate change risk suggested by proof of redox cycling of humic substances 2Radiation therapy for cervical cancer increases risk for colorectal cancer 2Genetic study tackles mystery of slow plant domestications 2Genetic study tackles mystery of slow plant domestications 3Genetic study tackles mystery of slow plant domestications 4
... Researchers at Albany Medical College are releasing results of a ... search for new drug targets aimed at preventing or reversing ... stroke. In the March 5 issue of the ... and his colleagues at the college,s Center for Cardiovascular Science ...
... , This release is available in German . ... beewolves, house beneficial bacteria on their cocoons that guarantee ... Institute for Chemical Ecology in Jena teamed up with ... Leibniz Institute for Natural Product Research Hans-Knoell-Institute - ...
... African-Americans age 65 and younger are more than twice ... any region, and people who have a stroke are more ... researchers at the University of Alabama at Birmingham (UAB) School ... for Geographic and Racial Differences in Stroke (REGARDS) study, one ...
Cached Biology News:Preventing or reversing inflammation after heart attack, stroke may require 2-pronged approach 2Beewolves protect their offspring with antibiotics 2Beewolves protect their offspring with antibiotics 3UAB study shows African-Americans have highest stroke rate, southerners more likely to die 2
For the quantitative determination of canine Interferon gamma,(IFN-γ) concentrations in cell culture supernates, serum and,plasma....
Request Info...
Homo sapiens olfactomedin 1, transcript variant 3...
Component of GELase™ Agarose Gel-Digesting Preparation. 1 ml of 50X Buffer is sufficient for replacing the buffer in at least 5 g of gel....
Biology Products: